Plasma Concentration Studies
GLP3-R
LY3437943
GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
99%+ Purity
Purity Tested
Research Use Only
Laboratory Use
Peptide Profile
Peptide Type
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
What Is Retatrutide?
Stability Information
Avoid freeze/thaw cycles. Protect from light
Lyophilized (powder)
-20°C • 24+ months
Reconstituted
2-8°C • ~30 days
Sources & References
Peer-reviewed research
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023 • DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
- View Source
The Lancet
Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
- View Source
Nature Medicine
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
- View Source
Lancet Diabetes & Endocrinology
Effects of Retatrutide on Body Composition
2025
Coskun T, et al.
- View Source
PubMed Central
Triple Agonism Based Therapies for Obesity
2025
- View Source
PubMed Central
Retatrutide — A Game Changer in Obesity Pharmacotherapy
2025
- View Source
PubMed Central
Efficacy and Safety of Retatrutide — Systematic Review & Meta-Analysis
2024
- View Source
Eli Lilly
TRIUMPH-4 Phase 3 Trial Results
2025
- View Source
Nature Cell Discovery
Structural Analysis of Incretin Receptor Agonists
2024
- View Source
PubChem Database
Retatrutide Compound Information
2025
- View Source
ClinicalTrials.gov
Retatrutide Clinical Trials Registry
2025
- View Source
